Table 1.
Patients characteristics of gefitinib and erlotinib cohort.
| Characteristic | Gefitinib cohort (n = 4340) | Erlotinib cohort (n = 1635) | ||||||
|---|---|---|---|---|---|---|---|---|
| PPI | H2RA | Non-user | P | PPI | H2RA | Non-user | P | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |||
| No. patients | 604 (13.9) | 894 (20.6) | 2842 (65.5) | 293 (17.9) | 426 (26.1) | 916 (56.0) | ||
| Gender | ||||||||
| Female | 359 (59.4) | 638 (71.4) | 1878 (66.1) | < 0.0001 | 148 (50.5) | 259 (60.8) | 495 (54.0) | 0.0143 |
| Male | 245 (40.6) | 256 (28.6) | 964 (33.9) | 145 (49.5) | 167 (39.2) | 421 (46.0) | ||
| Age (years) | ||||||||
| Mean (SD) | 68.7 (12.4) | 68.9 (12.5) | 66.3 (12.9) | < 0.0001 | 68.1 (10.8) | 66.7 (11.5) | 63.9 (12.3) | < 0.0001 |
| 20–65 | 226 (37.4) | 338 (37.8) | 1290 (45.4) | < 0.0001 | 111 (37.9) | 190 (44.6) | 492 (53.7) | < 0.0001 |
| ≥ 65 | 378 (62.6) | 556 (62.2) | 1552 (54.6) | 182 (62.1) | 236 (55.4) | 424 (46.3) | ||
| Stage | ||||||||
| IIIB | 28 (4.6) | 42 (4.7) | 108 (3.8) | 0.3861 | 6 (2.0) | 15 (3.5) | 34 (3.7) | 0.3801 |
| IV | 576 (95.4) | 852 (95.3) | 2734 (96.2) | 287 (98.0) | 411 (96.5) | 882 (96.3) | ||
| ECOG PS | ||||||||
| 0–1 | 363 (60.1) | 548 (61.3) | 2008 (70.7) | < 0.0001 | 205 (70.0) | 289 (67.8) | 695 (75.9) | 0.0032 |
| 2 | 112 (18.5) | 159 (17.8) | 365 (12.8) | 36 (12.3) | 72 (16.9) | 109 (11.9) | ||
| > 2 | 80 (13.3) | 126 (14.1) | 216 (7.6) | 28 (9.6) | 42 (9.9) | 52 (5.7) | ||
| Smoking status | ||||||||
| Non-smokers | 431 (71.4) | 680 (76.1) | 2213 (77.9) | 0.0104 | 205 (70.0) | 307 (72.1) | 631 (68.9) | 0.8344 |
| Smokers | 128 (21.2) | 166 (18.6) | 488 (17.2) | 69 (23.6) | 92 (21.6) | 220 (24.0) | ||
| CCI score | ||||||||
| 0 | 275 (45.5) | 429 (48.0) | 1749 (61.5) | < 0.0001 | 140 (47.8) | 215 (50.5) | 586 (64.0) | < 0.0001 |
| 1 | 173 (28.7) | 250 (28.0) | 690 (24.3) | 75 (25.6) | 117 (27.5) | 203 (22.2) | ||
| ≥ 2 | 156 (25.8) | 215 (24.1) | 403 (14.2) | 78 (26.6) | 94 (22.1) | 127 (13.9) | ||
| Insurance Income ranks | ||||||||
| No income | 216 (35.8) | 352 (39.4) | 1078 (37.93) | 0.0275 | 106 (36.2) | 153 (35.9) | 297 (32.4) | 0.1028 |
| ≤ 22,000 NTD | 177 (29.3) | 215 (24.1) | 663 (23.33) | 50 (17.1) | 80 (18.8) | 138 (15.1) | ||
| < 22,000 NTD | 211 (34.9) | 327 (36.6) | 1101 (38.74) | 137 (46.8) | 193 (45.3) | 481 (52.5) | ||
| PUD (%) | 281 (46.5) | 198 (22.2) | 99 (3.5) | < 0.0001 | 122 (41.6) | 77 (18.1) | 28 (3.1) | < 0.0001 |
| BSA (m2) | ||||||||
| Medain (Q1, Q3) | 1.6 (1.5, 1.7) | 1.6 (1.5, 1.7) | 1.6 (1.5, 1.7) | 1.6 (1.5, 1.7) | 1.6 (1.5, 1.7) | 1.6 (1.5, 1.8) | ||
| ≥ 1.6 | 257 (42.6) | 306 (34.2) | 1120 (39.4) | 0.0179 | 151 (51.5) | 180 (42.3) | 442 (48.3) | 0.1021 |
| < 1.6 | 293 (48.5) | 499 (55.8) | 1457 (51.3) | 122 (41.6) | 202 (47.4) | 396 (43.2) | ||
| Sterood user (%) | 241 (39.9) | 324 (36.2) | 631 (22.2) | 129 (44.0) | 189 (44.4) | 257 (28.1) | ||
| Steroid cDDD | ||||||||
| Mean (SD) | 49.1 (53.7) | 50.6 (59.1) | 44.3 (55.4) | 0.208 | 58.6 (58.9) | 67.2 (76.9) | 40 (44.9) | < 0.0001 |
There were missing data in ECOG PS (gefitinib: n = 363; erlotinib: n = 107), Smoking status (gefitinib: n = 234; erlotinib: n = 111) and BSA (gefitinib: n = 408; erlotinib: n = 142).
PPI proton pump inhibitor, H2RA histamine-2 receptor antagonist, ECOG PS Eastern Cooperative Oncology Group performance status, CCI charlson comorbidity index, NTD new Taiwan dollar, BSA body surface area, PUD peptic ulcer disease, cDDD cumulative defined daily doses.